ATROPINE SULFATE- atropine sulfate injection, solution

Atropine Sulfate by

Drug Labeling and Warnings

Atropine Sulfate by is a Prescription medication manufactured, distributed, or labeled by Henry Schein, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Atropine Sulfate Injection is indicated for temporary blockade of severe or life-threatening muscarinic
    effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic
    mushroom poisoning, and to treat bradyasystolic cardiac arrest.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Administration
    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to
    administration, whenever solution and container permit. Do not administer unless solution is clear and
    seal is intact. Each syringe is intended for single dose only. Discard unused portion.
    For intravenous administration.
    Titrate based on heart rate, PR interval, blood pressure and symptoms.


    2.2 Adult Dosage

    Image1.jpg

    2.3 Pediatric Dosage

    Dosing in pediatric populations has not been well studied. Usual initial dose is 0.01 to 0.03 mg/kg.
    2.4 Dosing in Patients with Coronary Artery Disease

    Limit the total dose of atropine sulfate to 0.03 mg/kg to 0.04 mg/kg [see Warnings and Precautions (5.1)]

  • 3 DOSAGE FORMS AND STRENGTHS

    Injection: 0.05 mg/mL and 0.1 mg/mL in Ansyr® Plastic Syringe.

    Injection: 0.1 mg/mL in LifeShield® Abboject® Glass Syringe.

    Injection: 0.1 mg/mL in Abboject® Syringe with Male Luer Lock Adapter.

  • 4 CONTRAINDICATIONS

    None.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Tachycardia
    When the recurrent use of atropine is essential in patients with coronary artery disease, the total dose
    should be restricted to 2 to 3 mg (maximum 0.03 to 0.04 mg/kg) to avoid the detrimental effects of
    atropine-induced tachycardia on myocardial oxygen demand.
    5.2 Acute Glaucoma
    Atropine may precipitate acute glaucoma.

    5.3 Pyloric Obstruction
    Atropine may convert partial organic pyloric stenosis into complete obstruction.
    5.4 Complete Urinary Retention
    Atropine may lead to complete urinary retention in patients with prostatic hypertrophy.
    5.5 Viscid Plugs
    Atropine may cause inspissation of bronchial secretions and formation of viscid plugs in patients with
    chronic lung disease.

  • 6 ADVERSE REACTIONS

    The following adverse reactions have been identified during post-approval use of atropine sulfate.
    Because these reactions are reported voluntarily from a population of uncertain size, it is not always
    possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
    Most of the side effects of atropine are directly related to its antimuscarinic action. Dryness of the mouth,
    blurred vision, photophobia and tachycardia commonly occur. Anhidrosis can produce heat intolerance.
    Constipation and difficulty in micturition may occur in elderly patients. Occasional hypersensitivity
    reactions have been observed, especially skin rashes which in some instances progressed to exfoliation.

  • 7 DRUG INTERACTIONS

    7.1 Mexiletine

    Atropine Sulfate Injection decreased the rate of mexiletine absorption without altering the relative oral
    bioavailability; this delay in mexiletine absorption was reversed by the combination of atropine and
    intravenous metoclopramide during pretreatment for anesthesia.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy
    Animal reproduction studies have not been conducted with atropine. It also is not known whether atropine
    can cause fetal harm when given to a pregnant woman or can affect reproduction capacity.
    8.3 Nursing Mothers
    Trace amounts of atropine was found in breast milk. The clinical impact of this is not known.
    8.4 Pediatric Use
    Recommendations for use in pediatric patients are not based on clinical trials.
    8.5 Geriatric Use
    An evaluation of current literature revealed no clinical experience identifying differences in response
    between elderly and younger patients. In general, dose selection for an elderly patient should be cautious,
    usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic,
    renal, or cardiac function, and of concomitant disease or other drug therapy.

  • 10 OVERDOSAGE

    Excessive dosing may cause palpitation, dilated pupils, difficulty in swallowing, hot dry skin, thirst,
    dizziness, restlessness, tremor, fatigue and ataxia. Toxic doses lead to restlessness and excitement,
    hallucinations, delirium and coma. Depression and circulatory collapse occur only with severe
    intoxication. In such cases, blood pressure declines and death due to respiratory failure may ensue
    following paralysis and coma.
    The fatal adult dose of atropine is not known. In pediatric populations, 10 mg or less may be fatal.
    In the event of toxic overdosage, a short acting barbiturate or diazepam may be given as needed to control
    marked excitement and convulsions. Large doses for sedation should be avoided because central
    depressant action may coincide with the depression occurring late in atropine poisoning. Central
    stimulants are not recommended.
    Physostigmine, given as an atropine antidote by slow intravenous injection of 1 to 4 mg (0.5 to 1 mg in
    pediatric populations), rapidly abolishes delirium and coma caused by large doses of atropine. Since
    physostigmine is rapidly destroyed, the patient may again lapse into coma after one to two hours, and
    repeated doses may be required.
    Artificial respiration with oxygen may be necessary. Ice bags and alcohol sponges help to reduce fever,
    especially in pediatric populations.
    Atropine is not removed by dialysis

  • 11 DESCRIPTION

    Atropine Sulfate Injection, USP is a sterile, nonpyrogenic isotonic solution of atropine sulfate
    monohydrate in water for injection with sodium chloride sufficient to render the solution isotonic. It is
    administered parenterally by intravenous injection.
    Each milliliter (mL) contains 0.1 mg (adult strength) or 0.05 mg (pediatric strength) of atropine sulfate
    monohydrate equivalent to 0.083 mg (adult strength) or 0.042 mg (pediatric strength) of atropine, and
    sodium chloride, 9 mg. May contain sodium hydroxide and/or sulfuric acid for pH adjustment
    0.308 mOsmol/mL (calc.). pH 3.0 to 6.5.
    Sodium chloride added to render the solution isotonic for injection of the active ingredient is present in
    amounts insufficient to affect serum electrolyte balance of sodium (Na+
    ) and chloride (Cl-
    ) ions.
    The solution contains no bacteriostat, antimicrobial agent or added buffer (except for pH adjustment) and
    is intended for use only as a single-dose injection. When smaller doses are required the unused portion
    should be discarded.
    Atropine Sulfate, USP is chemically designated 1α H, 5α H-Tropan-3-α-ol (±)-tropate (ester), sulfate (2:1)
    (salt) monohydrate, (C17H23NO3)2 H2SO4 H2O, colorless crystals or white crystalline powder very
    soluble in water. It has the following structural formula:

    Formula1.jpg

    Atropine, a naturally occurring belladonna alkaloid, is a racemic mixture of equal parts of d- and
    1-hyocyamine, whose activity is due almost entirely to the levo isomer of the drug.
    Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water.
    The Ansyr® syringe is molded from a specially formulated polypropylene. Water permeates from inside
    the container at an extremely slow rate which will have an insignificant effect on solution concentration
    over the expected shelf life. Solutions in contact with the plastic container may leach out certain chemical
    components from the plastic in very small amounts; however, biological testing was supportive of the
    safety of the syringe material

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action
    Atropine is an antimuscarinic agent since it antagonizes the muscarine-like actions of acetylcholine and
    other choline esters.
    Atropine inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic
    cholinergic nerves, and on smooth muscles which respond to endogenous acetylcholine but are not so
    innervated. As with other antimuscarinic agents, the major action of atropine is a competitive or
    surmountable antagonism which can be overcome by increasing the concentration of acetylcholine at
    receptor sites of the effector organ (e.g., by using anticholinesterase agents which inhibit the enzymatic
    destruction of acetylcholine). The receptors antagonized by atropine are the peripheral structures that are
    stimulated or inhibited by muscarine (i.e., exocrine glands and smooth and cardiac muscle). Responses to
    postganglionic cholinergic nerve stimulation also may be inhibited by atropine but this occurs less readily
    than with responses to injected (exogenous) choline esters.
    12.2 Pharmacodynamics
    Atropine-induced parasympathetic inhibition may be preceded by a transient phase of stimulation,
    especially on the heart where small doses first slow the rate before characteristic tachycardia develops due
    to paralysis of vagal control. Atropine exerts a more potent and prolonged effect on heart, intestine and
    bronchial muscle than scopolamine, but its action on the iris, ciliary body and certain secretory glands is
    weaker than that of scopolamine. Unlike the latter, atropine in clinical doses does not depress the central
    nervous system but may stimulate the medulla and higher cerebral centers. Although mild vagal excitation
    occurs, the increased respiratory rate and (sometimes) increased depth of respiration produced by atropine
    are more probably the result of bronchiolar dilatation. Accordingly, atropine is an unreliable respiratory
    stimulant and large or repeated doses may depress respiration.
    Adequate doses of atropine abolish various types of reflex vagal cardiac slowing or asystole. The drug
    also prevents or abolishes bradycardia or asystole produced by injection of choline esters,

    anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation
    of the vagus. Atropine also may lessen the degree of partial heart block when vagal activity is an etiologic
    factor. In some patients with complete heart block, the idioventricular rate may be accelerated by atropine;
    in others, the rate is stabilized. Occasionally a large dose may cause atrioventricular (A-V) block and
    nodal rhythm.
    Atropine Sulfate Injection in clinical doses counteracts the peripheral dilatation and abrupt decrease in
    blood pressure produced by choline esters. However, when given by itself, atropine does not exert a
    striking or uniform effect on blood vessels or blood pressure. Systemic doses slightly raise systolic and
    lower diastolic pressures and can produce significant postural hypotension. Such doses also slightly
    increase cardiac output and decrease central venous pressure. Occasionally, therapeutic doses dilate
    cutaneous blood vessels, particularly in the “blush” area (atropine flush) and may cause atropine “fever”
    due to suppression of sweat gland activity in infants and small children.
    The effects of intravenous atropine on heart rate (maximum heart rate) and saliva flow (minimum flow)
    after intravenous administration (rapid, constant infusion over 3 min.) are delayed by 7 to 8 minutes after
    drug administration and both effects are non-linearly related to the amount of drug in the peripheral
    compartment. Changes in plasma atropine levels following intramuscular administration (0.5 to
    4 mg doses) and heart rate are closely overlapped but the time course of the changes in atropine levels and
    behavioral impairment indicates that pharmacokinetics is not the primary rate-limiting mechanism for the
    central nervous system effect of atropine.
    12.3 Pharmacokinetics
    Atropine disappears rapidly from the blood following injection and is distributed throughout the body.
    Exercise, both prior to and immediately following intramuscular administration of atropine, significantly
    increases the absorption of atropine due to increased perfusion in the muscle and significantly decreases
    the clearance of atropine. The pharmacokinetics of atropine is nonlinear after intravenous administration
    of 0.5 to 4 mg. Atropine’s plasma protein binding is about 44% and saturable in the 2-20 μg/mL
    concentration range. Atropine readily crosses the placental barrier and enters the fetal circulation, but is
    not found in amniotic fluid. Much of the drug is destroyed by enzymatic hydrolysis, particularly in the
    liver; from 13 to 50% is excreted unchanged in the urine. Traces are found in various secretions, including
    milk. The major metabolites of atropine are noratropine, atropin-n-oxide, tropine, and tropic acid. The
    metabolism of atropine is inhibited by organophosphate pesticides.
    Specific Populations
    The elimination half-life of atropine is more than doubled in children under two years and the elderly
    (>65 years old) compared to other age groups. There is no gender effect on the pharmacokinetics and
    pharmacodynamics (heart rate changes) of atropine.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
    Studies have not been performed to evaluate the carcinogenic or mutagenic potential of atropine or its
    potential to affect fertility adversely.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Atropine Sulfate Injection, USP is supplied in single-dose syringes as follows:

    Image2.jpg

    Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).
    [See USP Controlled Room Temperature.]

     Product repackaged by: Henry Schein, Inc., Bastian, VA 24314
    From Original Manufacturer/Distributor's NDC and Unit of SaleTo Henry Schein Repackaged Product NDC and Unit of SaleTotal Strength/Total Volume (Concentration) per unit
    NDC: 0409-9630-05
    Bundle of 10
    Ansyr™ Plastic Syringe    		NDC: 0404-9823-05
    1 Ansyr™ Plastic Syringe in a bag
    (Vial bears NDC: 0409-9630-15)    		Concentration: 0.05 mg/mL
    Fill Volume: 5 mL
    Total Atropine Content: 0.25 mg

    Distributed by Hospira, Inc., Lake Forest, IL 60045 USA
    Abboject® is a trademark of Abbott Laboratories.
    LifeShield® is the trademark of ICU Medical, Inc. and is used under license.

    LAB-1041-4.2

  • SAMPLE PACKAGE LABEL

    Label1.jpg

  • INGREDIENTS AND APPEARANCE
    ATROPINE SULFATE  
    atropine sulfate injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0404-9823(NDC:0409-9630)
    Route of AdministrationINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, ENDOTRACHEAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Atropine Sulfate (UNII: 03J5ZE7KA5) (Atropine - UNII:7C0697DR9I) Atropine Sulfate0.05 mg  in 1 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0404-9823-051 in 1 BAG01/09/2022
    15 mL in 1 SYRINGE, PLASTIC; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02114601/09/2022
    Labeler - Henry Schein, Inc. (012430880)
    • © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.